National ALS Clinic and Research Group, Beaumont Hospital Dublin/Academic Unit of Neurology

Trinity College Dublin

The National ALS Clinic and Research Group based at Beaumont Hospital Dublin provides a multidisciplinary service to the entire Irish ALS population.

 

Trinity College Dublin

The National ALS Clinical and Research Group undertakes research in epidemiology, cognition, genetics, bioinformatics, drug development and novel biomarker development, and commercial and investigator led clinical trials of novel compounds in ALS. Much of our clinical research is supported by the charity Research Motor Neurone.

Contact
Location
School of Medicine, Trinity Biomedical Sciences Institute, Pearse Street, Dublin 2, Dublin, Ireland

Our Specialists

Orla Hardiman

Professor of Neurology

Professor Hardiman trained in Neurology in Boston prior to her appointment as […]

Orla Hardiman
Current trials
Recruiting
Phase ii

DAZALS trial

Industry trial
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more